Eisai Launches Treakisym As Its First Cancer Drug In Japan
This article was originally published in PharmAsia News
Executive Summary
Eisai launched its first cancer drug in Japan, its Treakisym (bendamustine) for B-cell non-Hodgkin's lymphoma and mantle-cell lymphoma